Assembly Biosciences’ (ASMB) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a research note issued to investors on Monday morning,Benzinga reports. HC Wainwright also issued estimates for Assembly Biosciences’ Q1 2025 earnings at ($1.54) EPS, Q2 2025 earnings at ($1.54) EPS, Q3 2025 earnings at ($1.64) EPS, Q4 2025 earnings at ($1.57) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($9.05) EPS, FY2027 earnings at ($12.07) EPS, FY2028 earnings at ($12.32) EPS and FY2029 earnings at ($12.58) EPS.

Assembly Biosciences Trading Down 5.3 %

ASMB opened at $10.81 on Monday. The business has a 50 day moving average of $12.70 and a 200-day moving average of $15.02. The stock has a market capitalization of $68.71 million, a price-to-earnings ratio of -1.61 and a beta of 0.62. Assembly Biosciences has a 1-year low of $10.27 and a 1-year high of $19.93.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.75) by $0.18. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. The firm had revenue of $7.36 million during the quarter, compared to the consensus estimate of $7.05 million. Equities analysts predict that Assembly Biosciences will post -6.87 EPS for the current year.

Insider Buying and Selling

In other news, Director Michael Houghton bought 3,202 shares of Assembly Biosciences stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average cost of $15.61 per share, with a total value of $49,983.22. Following the completion of the transaction, the director now directly owns 3,202 shares in the company, valued at $49,983.22. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Assembly Biosciences

Hedge funds have recently made changes to their positions in the business. Gilead Sciences Inc. bought a new stake in Assembly Biosciences in the fourth quarter valued at about $34,865,000. Peapod Lane Capital LLC bought a new stake in shares of Assembly Biosciences in the 4th quarter valued at approximately $994,000. B Group Inc. bought a new stake in shares of Assembly Biosciences in the 4th quarter valued at approximately $799,000. Monimus Capital Management LP acquired a new position in shares of Assembly Biosciences in the 4th quarter worth approximately $664,000. Finally, Renaissance Technologies LLC lifted its position in shares of Assembly Biosciences by 44.3% during the 4th quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company’s stock worth $1,495,000 after buying an additional 29,087 shares during the period. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.